NO983284L - Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser. - Google Patents
Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser.Info
- Publication number
- NO983284L NO983284L NO19983284A NO983284A NO983284L NO 983284 L NO983284 L NO 983284L NO 19983284 A NO19983284 A NO 19983284A NO 983284 A NO983284 A NO 983284A NO 983284 L NO983284 L NO 983284L
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal antibody
- embolism
- thrombosis
- medicament
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1010896P | 1996-01-17 | 1996-01-17 | |
US2911996P | 1996-10-24 | 1996-10-24 | |
PCT/US1997/000759 WO1997026010A1 (en) | 1996-01-17 | 1997-01-17 | Anticoagulant agents useful in treatment of thrombosis |
Publications (2)
Publication Number | Publication Date |
---|---|
NO983284D0 NO983284D0 (no) | 1998-07-16 |
NO983284L true NO983284L (no) | 1998-09-16 |
Family
ID=26680794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19983284A NO983284L (no) | 1996-01-17 | 1998-07-16 | Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser. |
Country Status (26)
Country | Link |
---|---|
US (5) | US6005091A (de) |
EP (2) | EP1832297A1 (de) |
JP (2) | JP2000503210A (de) |
KR (1) | KR100553629B1 (de) |
CN (1) | CN1213312A (de) |
AR (1) | AR005658A1 (de) |
AT (1) | ATE330630T1 (de) |
AU (1) | AU706397B2 (de) |
BR (1) | BR9707049A (de) |
CZ (1) | CZ299452B6 (de) |
DE (1) | DE69736197T2 (de) |
DK (1) | DK1007089T3 (de) |
ES (1) | ES2267131T3 (de) |
HK (1) | HK1029513A1 (de) |
HU (1) | HU225903B1 (de) |
ID (1) | ID17156A (de) |
IL (1) | IL125380A0 (de) |
MA (1) | MA24512A1 (de) |
MX (1) | MX9805810A (de) |
NO (1) | NO983284L (de) |
NZ (2) | NZ501215A (de) |
PL (1) | PL187274B1 (de) |
PT (1) | PT1007089E (de) |
SI (1) | SI1007089T1 (de) |
TR (1) | TR199801390T2 (de) |
WO (1) | WO1997026010A1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
US20040038898A1 (en) * | 1996-05-16 | 2004-02-26 | The Trustees Of Columbia University | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
WO1999001476A1 (en) * | 1997-07-03 | 1999-01-14 | Smithkline Beecham Corporation | CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN |
DE19802139C1 (de) * | 1998-01-22 | 1999-09-23 | Centeon Pharma Gmbh | Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung |
WO1999058680A2 (en) * | 1998-05-08 | 1999-11-18 | Stichting Sanquin Bloedvoorziening | Method for diagnosis and treatment of haemophilia a patients with an inhibitor |
US7250494B2 (en) * | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
WO2000007626A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
AU766551C (en) * | 1998-08-28 | 2005-02-17 | Genentech Inc. | Human anti-factor IX/IXa antibodies |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
WO2000026394A1 (en) * | 1998-10-31 | 2000-05-11 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
CA2381125C (en) * | 1999-07-14 | 2013-04-23 | D. Collen Research Foundation Vzw | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
US7067313B1 (en) | 1999-07-14 | 2006-06-27 | D. Collen Research Foundation | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
US6316259B1 (en) * | 2000-01-21 | 2001-11-13 | Isis Pharmaceuticals, Inc. | Antisense inhibition of glycogen synthase kinase 3 alpha expression |
EP1825864A3 (de) * | 2000-05-15 | 2007-09-12 | SmithKline Beecham Corporation | Anthithrombose Agenzien |
US7312325B2 (en) * | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
DK1222929T3 (da) | 2001-01-11 | 2010-09-06 | Life Sciences Res Partners Vzw | Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom |
CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
CA2418808A1 (en) * | 2001-06-12 | 2002-12-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human-type anti-blood coagulation factor viii antibody |
EP1416964A4 (de) * | 2001-07-09 | 2005-10-12 | Aphton Corp | Behandlung und prävention von kanzerösen und präkanzerösen zuständen von leber, lunge und ösophagus |
US20080219998A1 (en) * | 2001-12-07 | 2008-09-11 | Andras Gruber | Anti-Thrombotic Agents |
US20040052779A1 (en) * | 2001-12-21 | 2004-03-18 | Stinson Jeffrey R. | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
AU2003248744C1 (en) | 2002-06-28 | 2009-12-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors |
US6928528B1 (en) | 2002-10-07 | 2005-08-09 | Advanced Micro Devices, Inc. | Guaranteed data synchronization |
KR20050118690A (ko) * | 2003-03-28 | 2005-12-19 | 애프톤 코포레이션 | 가스트린 호르몬 면역어세이 |
JP4422430B2 (ja) | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び/又はプロゲストゲン含有外用貼付剤 |
US7785594B2 (en) | 2003-08-14 | 2010-08-31 | Life Sciences Research Partners Vzw | Factor VIII inhibitory antibodies with reduced glycosylation |
US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
WO2005035754A1 (ja) * | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
WO2005095459A2 (en) * | 2004-03-29 | 2005-10-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
DK1794586T3 (da) | 2004-09-22 | 2013-05-13 | Cancer Advances Inc | Monoklonale antistoffer til progastrin |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
WO2008067056A2 (en) * | 2006-10-16 | 2008-06-05 | Novelmed Therapeutics, Inc. | Method of inhibiting coagulation with human anti-factor va antibodies and use thereof |
US20100239570A1 (en) * | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
AU2008299516B2 (en) | 2007-09-13 | 2013-09-12 | Delenex Therapeutics Ag | Humanized antibodies against the beta-amyloyd peptide |
EP3127921A1 (de) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr |
US8187591B2 (en) * | 2007-10-11 | 2012-05-29 | The Regents Of The University Of California | Methods of treating coagulopathy |
HUE041556T2 (hu) * | 2008-06-19 | 2019-05-28 | Prothix Bv | XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére |
KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
CA2893977C (en) | 2012-12-21 | 2024-02-13 | Seattle Genetics, Inc. | Anti-ntb-a antibodies and related compositions and methods |
WO2014160088A2 (en) * | 2013-03-14 | 2014-10-02 | Rhode Island Hospital, A Lifespan-Partner | Treating hepatitis b virus infections |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
NZ728425A (en) | 2014-08-07 | 2022-05-27 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
AU2017209083A1 (en) | 2016-01-22 | 2018-07-12 | Adimab, Llc | Anti-coagulation factor XI antibodies |
TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
SG10202103120UA (en) | 2016-06-14 | 2021-05-28 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
IL265144B1 (en) | 2016-09-06 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Methods for using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
CN110325211A (zh) * | 2016-12-23 | 2019-10-11 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
EP3559047A1 (de) | 2016-12-23 | 2019-10-30 | Novartis AG | Faktor xi-antikörper und verfahren zur verwendung |
EP3624841A4 (de) | 2017-06-15 | 2021-01-27 | Cancer Advances, Inc., | Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs |
GB201709970D0 (en) * | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
PE20210005A1 (es) | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo |
BR112021012065A2 (pt) | 2018-12-21 | 2021-12-07 | Kymab Ltd | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3909799A1 (de) * | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2049655C (en) * | 1990-09-17 | 1996-11-12 | Akio Odawara | Pharmaceutical composition for inhibiting platelet aggregation |
WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
DK0658168T3 (da) * | 1992-08-27 | 2001-01-22 | Sanquin Bloedvoorziening | Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p |
US5397581A (en) * | 1993-02-05 | 1995-03-14 | Lerman; Russell E. | Means for continuous confectionery coating of edible centers |
MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
US20070190059A1 (en) * | 1996-01-17 | 2007-08-16 | Smithkline Beecham Corporation | Antithrombotic agents |
-
1997
- 1997-01-15 MA MA24467A patent/MA24512A1/fr unknown
- 1997-01-16 US US08/783,853 patent/US6005091A/en not_active Expired - Fee Related
- 1997-01-17 DE DE69736197T patent/DE69736197T2/de not_active Expired - Fee Related
- 1997-01-17 TR TR1998/01390T patent/TR199801390T2/xx unknown
- 1997-01-17 DK DK97903837T patent/DK1007089T3/da active
- 1997-01-17 HU HU9900396A patent/HU225903B1/hu not_active IP Right Cessation
- 1997-01-17 BR BR9707049-1A patent/BR9707049A/pt not_active Application Discontinuation
- 1997-01-17 ES ES97903837T patent/ES2267131T3/es not_active Expired - Lifetime
- 1997-01-17 SI SI9730743T patent/SI1007089T1/sl unknown
- 1997-01-17 IL IL12538097A patent/IL125380A0/xx unknown
- 1997-01-17 PL PL97327929A patent/PL187274B1/pl not_active IP Right Cessation
- 1997-01-17 JP JP9526207A patent/JP2000503210A/ja not_active Ceased
- 1997-01-17 WO PCT/US1997/000759 patent/WO1997026010A1/en active IP Right Grant
- 1997-01-17 AR ARP970100204A patent/AR005658A1/es active IP Right Grant
- 1997-01-17 EP EP06012602A patent/EP1832297A1/de not_active Withdrawn
- 1997-01-17 AT AT97903837T patent/ATE330630T1/de not_active IP Right Cessation
- 1997-01-17 KR KR1019980705476A patent/KR100553629B1/ko not_active IP Right Cessation
- 1997-01-17 AU AU18308/97A patent/AU706397B2/en not_active Ceased
- 1997-01-17 NZ NZ501215A patent/NZ501215A/en unknown
- 1997-01-17 CZ CZ0222598A patent/CZ299452B6/cs not_active IP Right Cessation
- 1997-01-17 ID IDP970140A patent/ID17156A/id unknown
- 1997-01-17 CN CN97192981A patent/CN1213312A/zh active Pending
- 1997-01-17 PT PT97903837T patent/PT1007089E/pt unknown
- 1997-01-17 EP EP97903837A patent/EP1007089B1/de not_active Expired - Lifetime
- 1997-01-17 NZ NZ331014A patent/NZ331014A/xx unknown
-
1998
- 1998-07-16 NO NO19983284A patent/NO983284L/no not_active Application Discontinuation
- 1998-07-17 MX MX9805810A patent/MX9805810A/es not_active IP Right Cessation
-
1999
- 1999-06-25 US US09/344,050 patent/US6391299B1/en not_active Expired - Fee Related
-
2000
- 2000-11-21 HK HK00107441A patent/HK1029513A1/xx not_active IP Right Cessation
-
2002
- 2002-01-17 US US10/051,852 patent/US20020146411A1/en not_active Abandoned
-
2005
- 2005-08-11 US US11/201,592 patent/US20070003553A1/en not_active Abandoned
-
2007
- 2007-01-16 US US11/623,496 patent/US20070224198A1/en not_active Abandoned
- 2007-08-06 JP JP2007204012A patent/JP2007325602A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO983284L (no) | Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser. | |
EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
NO911694L (no) | Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav. | |
DK0666086T3 (da) | Ledetråd til medicinsk formål, og fremgangsmåde til fremstilling af spiral derfor | |
IL133422A0 (en) | Optical device, method of cleaning the same, projection aligner, and method of producing the same | |
NO20004098L (no) | FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser | |
FI960089A (fi) | Proteiinikinaasi C:n oligonukleotidimodulaatio | |
NO20063000L (no) | Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav. | |
NO904696L (no) | Elektrostatisk, flytende fremkaller og fremgangsmaate for fremstilling av denne. | |
DE3889062D1 (de) | Monoklonaler Antikörper gegen humanen BCDF. | |
DK91793D0 (da) | Fremgangsmaade til overfladebehandling, midler til udoevelse og anvendelsen heraf | |
NO902809D0 (no) | Anordning og fremgangsmaate for fremstilling av syntesegass, samt anvendelse av denne. | |
NO895334D0 (no) | Elektrostatisk, flytende fremkaller og fremgangsmaate for fremstilling av denne. | |
ITGE940100A0 (it) | Procedimento e dispositivo per la produzione di un filo ritorto. | |
NO20001758D0 (no) | Fremgangsmåter og blandinger for behandling av leddgikt | |
DK0819113T3 (da) | Benzamider til behandling af neurodegenerative forstyrrelser | |
NO894758L (no) | Produkt med hylster og fremgangsmaate for fremstilling av produktet. | |
NO913117D0 (no) | Fremgangsmaate for behandling av benoedeleggende sykdommer. | |
ITRM930502A0 (it) | Procedimento per la produzione di r amminocarnitina e s amminocarnitina. | |
NO912368L (no) | Bygning og fremgangsmaate for bygging av denne. | |
DK0981349T3 (da) | 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme | |
WO1994018988A3 (en) | Use of heparins for the treatment of inflammatory or immunological diseases | |
BR9608595A (pt) | Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais | |
DK0866699T3 (da) | Anvendelse af cholinesteraseinhibitorer til fremstilling af et medikament til behandling af xerostomi | |
NO904029D0 (no) | Elektrostatisk, flytende fremkaller og fremstilling av denne. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |